STOCK TITAN

Sonoma Pharmaceu - SNOA STOCK NEWS

Welcome to our dedicated page for Sonoma Pharmaceu news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceu stock.

Overview of Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals (SNOA) is a specialty pharmaceutical company dedicated to the research, development, and production of stabilized hypochlorous acid (HOCl) products. Utilizing its patented Microcyn technology, the company has built a robust portfolio designed for applications in wound care, dermatology, eye care, oral care, and animal health. By combining innovative, biocompatible formulations with rigorous clinical evidence, Sonoma Pharmaceuticals offers products that naturally address skin abrasions, irritation, scarring, and infection—providing clinicians and consumers reliable therapeutic options.

Core Business Areas and Technological Innovations

At the heart of Sonoma Pharmaceuticals’ operations is its groundbreaking use of stabilized hypochlorous acid. This naturally occurring molecule is proven to reduce itch, pain, inflammation, and the risk of infection while preserving healthy tissue. The company’s proprietary Microcyn technology facilitates the formulation of products that are non-toxic and highly effective across multiple treatment areas. Sonoma’s offerings include antimicrobial facial cleansers, wound care gels, skin barrier creams, and prescription products for managing dermatoses. Each product has been developed through in-vitro and clinical studies that confirm safety and effectiveness, reinforcing the company’s emphasis on scientific validation and quality.

Product Portfolio and Market Significance

Sonoma Pharmaceuticals’ diverse product range covers both over-the-counter and prescription segments. Its products address common but challenging conditions such as:

  • Wound Care: Products that promote healing of both acute and chronic wounds, minimizing pain and scarring.
  • Dermatological Applications: Solutions to manage conditions including acne, atopic dermatitis, and various forms of scarring.
  • Eye and Facial Care: Formulations that gently cleanse and relieve irritation around the eyes and face without harsh chemicals.
  • Animal Health: Specialized products designed for safe and effective treatment of skin issues in animals.

This wide-ranging portfolio positions the company as an influential player in the specialty pharmaceuticals space. Its products are clinically validated for applications that range from managing surgical scars to everyday skin irritations, making them integral to both clinical practice and consumer health care routines.

Global Distribution and Operational Footprint

Operating in markets across the United States, Latin America, Europe, Asia, and beyond, Sonoma Pharmaceuticals advances its mission through both direct sales and strategic partnerships. This dual-channel approach not only enhances distribution but also ensures that products are available in diverse healthcare settings, including hospitals, clinics, and retail outlets. Strategic collaborations with global distributors allow Sonoma to continue expanding its reach while maintaining stringent quality and compliance standards.

Regulatory Excellence and Commitment to Quality

Sonoma Pharmaceuticals has successfully attained numerous regulatory clearances, underscoring its commitment to safety and efficacy. With designations such as FDA 510(k) clearances and compliance with the European Union Medical Device Regulation (MDR), the company validates its product safety through rigorous and ongoing biocompatibility and performance testing. These approvals not only support the clinical effectiveness of its therapies but also reinforce the trust placed in its innovative solutions by healthcare professionals around the world.

Scientific Rigor and Clinical Validation

Scientific integrity is an essential element of Sonoma’s approach. Every formulation is the product of extensive research and testing, embodying the company’s dedication to evidence-based solutions. In-vitro studies and clinical trials have consistently demonstrated that Sonoma’s HOCl products are capable of managing skin abrasions, lacerations, and other minor injuries effectively. By continuously evolving based on scientific and clinical feedback, the company maintains its reputation as an authority in the field of specialized skin care and wound management.

Industry Recognition and Market Dynamics

Within the competitive landscape, Sonoma Pharmaceuticals distinguishes itself not by speculative claims about future growth but by its solid contributions to improving healthcare outcomes through validated, biocompatible products. The careful orchestration of product innovation, quality control, and strategic distribution has carved out a niche where effective treatment meets safety. This positioning makes the company a noteworthy subject of discussion for both industry experts and investors seeking an in-depth understanding of the underlying business model of specialty pharmaceuticals.

Conclusion

Sonoma Pharmaceuticals, Inc. stands as a compelling example of how specialized medical innovation can be translated into a consistent, scientifically backed product portfolio. Its commitment to patient safety, evidence-based research, and regulatory excellence forms the backbone of a diversified business model that addresses critical needs in wound and skin care. With products designed to relieve pain, reduce scarring, and promote healing, Sonoma not only meets current market demands but also sets a high standard in the realms of dermatological and antimicrobial care.

Rhea-AI Summary
Sonoma Pharmaceuticals Expands Microcyn NPWT Solution Product Line in the United States, Showcasing at CPHI Japan and SAWC Spring Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
none
-
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) announced a recent publication in Neurourology and Urodynamics highlighting the potential of Microdox in managing urinary tract infections in children with neurogenic or non-neurogenic bladder dysfunction. Microdox, based on Sonoma's patented Microcyn technology, is licensed for UTI prevention and treatment in Australia and New Zealand. The publication suggests that electrochemically activated solutions like Microdox could significantly improve outcomes for high-risk patients, with evidence from clinical trials supporting its short-term effectiveness. Sonoma aims to enhance patient quality of life through ongoing research and future trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (SNOA) will be presenting at two upcoming investor conferences in Denver and New York. The company will be presenting at the Trickle Research Spring 2024 Microcap Conference in Denver on April 2nd, 2024, and at the 14th Annual LD Micro Invitational in New York on April 8th - 9th, 2024. Amy Trombly, the CEO of Sonoma, will be leading the presentations at both events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
conferences
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) emphasizes the safety advantages of its Microcyn technology products over benzoyl peroxide-containing dermatology products. Recent concerns about benzene formation in popular dermatology products have led to a citizen petition for an FDA recall. Sonoma's Microcyn products, based on hypochlorous acid, are clinically proven to remove microorganisms safely and manage skin irritations without using benzoyl peroxide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
-
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA) reported a 7% increase in revenues compared to the previous year and a 15% increase from the prior quarter. The company also saw a 19% improvement in gross margin and a net loss of $1.0 million for the quarter. Sonoma's expansion efforts and cost control measures have positively impacted its financial results. The company also announced the launch of new products and partnerships, including Lumacyn Clarifying Mist and an agreement with NovaBay Pharmaceuticals, Inc. for the sale and marketing of Avenova-branded products in the European Union.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) has announced the launch of LumacynTM Clarifying Mist, an anti-inflammatory and antibacterial spray for over-the-counter use in the United States. The product is based on Sonoma's patented stabilized hypochlorous acid and is designed to soothe the skin, reduce redness, manage blemishes, and is safe for all ages and skin types. The company aims to provide consumers with a premium skincare product that harnesses the healing properties of their Microcyn technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) and Sonoma Pharmaceuticals, Inc. (SNOA) have announced an agreement for the sale and marketing of Avenova-branded products in the European Union. Sonoma will combine its existing eye product Ocudox with Avenova branding and market it through its established European distribution network. Sonoma will pay NovaBay a royalty fee based on net product sales of Ocudox by Avenova, and Sonoma will continue to market its Ocudox product in the European Union.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) and Sonoma Pharmaceuticals, Inc. (SNOA) have announced an agreement for the sale and marketing of Avenova-branded products by Sonoma in the European Union. The products will combine Sonoma's existing eye product Ocudox with Avenova branding and will be marketed through Sonoma's established European distribution network. Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay's Avenova products and will pay NovaBay a royalty fee based on net product sales. This agreement allows NovaBay to capitalize on sales of hypochlorous acid eye care products in the European Union, potentially doubling its sales of Avenova. NovaBay will continue to be the exclusive seller of Avenova branded products in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) announced a 36% gross profit percentage for the quarter, up 1% from the first fiscal quarter 2024. Total operating expenses decreased for the quarter and six months ended September 30, 2023, compared to the same period the prior year. European revenues increased 3% for the quarter and 13% for the six months ended September 30, 2023. The company reported a net loss of $2.9 million for the six months ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. has announced the U.S. launch of its intraoperative pulse lavage irrigation treatment. The product, developed using Sonoma's Microcyn® Technology, replaces non-antimicrobial saline and aggressive rinsing solutions with a safe and effective solution that can prevent infection and improve healing time. The treatment is cost competitive with IV bags and can be used in a variety of surgical procedures. Sonoma is introducing the product at the Symposium on Advanced Wound Care Fall Conference in Las Vegas and expects it to be ready for commercial use in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
none

FAQ

What is the current stock price of Sonoma Pharmaceu (SNOA)?

The current stock price of Sonoma Pharmaceu (SNOA) is $2.17 as of April 1, 2025.

What is the market cap of Sonoma Pharmaceu (SNOA)?

The market cap of Sonoma Pharmaceu (SNOA) is approximately 3.6M.

What products does Sonoma Pharmaceuticals develop?

The company develops stabilized hypochlorous acid (HOCl) based products, including wound care gels, scar management solutions, skin barrier creams, antimicrobial facial cleansers, and eye care formulations. These products serve both over-the-counter and prescription markets.

How does the patented Microcyn technology work?

Microcyn technology stabilizes hypochlorous acid to create non-toxic, biocompatible formulations. This technology ensures that the products are effective in reducing pain, scarring, and inflammation while preserving healthy tissues.

Which therapeutic areas does Sonoma Pharmaceuticals target?

Sonoma targets various therapeutic areas including wound care, dermatology (for conditions like acne, atopic dermatitis, and scarring), eye care, oral and nasal care, and animal health. This diverse portfolio addresses both chronic and acute conditions.

In which markets does Sonoma Pharmaceuticals operate?

The company operates internationally, with its products marketed and distributed in the United States, Latin America, Europe, Asia, and other global regions through direct sales and strategic partnerships.

What regulatory clearances have Sonoma Pharmaceuticals achieved?

Sonoma has received multiple regulatory clearances, including FDA 510(k) approvals and compliance with European Union Medical Device Regulations. These clearances validate the safety, efficacy, and biocompatibility of its products.

How does Sonoma differentiate itself from competitors in the HOCl market?

Sonoma differentiates itself through its patented Microcyn technology, rigorous clinical testing, strong regulatory track record, and a broad product portfolio addressing various skin and wound care needs. Its focus on scientific evidence and clinical validation supports its reputation for quality and safety.

What benefits do Sonoma’s products offer to consumers?

Consumers benefit from products that are clinically proven to reduce itching, pain, scarring, and irritation. The formulations provide effective solutions for treating minor injuries, managing chronic conditions, and ensuring gentle yet effective care for both human and animal skin.
Sonoma Pharmaceu

Nasdaq:SNOA

SNOA Rankings

SNOA Stock Data

3.56M
1.59M
1.25%
1.26%
0.6%
Drug Manufacturers - Specialty & Generic
Surgical & Medical Instruments & Apparatus
Link
United States
BOULDER